Abstract
Objective To characterize trends in prevalence of ASCVD, risk-factor control and medication use among adults with atherosclerotic cardiovascular disease (ASCVD), with frequent update of relevant guidelines.
Patients and Methods We conducted a cross-sectional analysis of data from 55,081 adults in the National Health and Nutrition Examination Surveys (NHANES) 1999-2018.
Results The age-standardized prevalence of ASCVD did not change significantly from 1999-2002 (7.9%, CI 7.1%-8.7%) to 2015-2018 (7.5%, CI 6.8%-8.3%) (P for trend =0.18). Over 60.0% ASCVD participants had very-high risk. The percentage with blood-pressure control (<130/80 mmHg) increased from 51.2% (CI, 41.0%-61.3%) in 1999-2002 to 57.2% (CI, 48.4%-65.6%) in 2011-2014, but then declined to 52.8% (CI, 44.4%-81.3%) in 2015-2018. From 1999-2002 to 2015-2018, the percentage with lipid control (non-high-density lipoprotein cholesterol <100 mg/dL) increased from 7.0% (CI, 3.5%-12.3%) to 26.4% (CI, 16.2%-38.9%), and with glycemic control (HbA1c <7.0%) decreased from 95.0% (CI, 90.2%-97.9%) to 84.0% (CI, 75.9%-90.3%). The percentage who achieved all 3 targets was 18.6% (CI, 8.2%-33.8%) in 2015-2018. After 2014, the percentages with blood-pressure, lipid, and glycemic control decreased in very-high-risk ASCVD, but increased in not-very-high-risk ASCVD. The percentage of ASCVD participants who used statins increased from 1999-2002 to 2011-2014, but then leveled off. The percentage who used blood-pressure-lowering drugs remained largely constant, and who used glucose-lowering drugs increased.
Conclusions The prevalence of ASCVD generally remained stable, with over 60.0% had very-high risk. Blood-pressure, lipid, and glycemic control decreased in very-high-risk ASCVD but increased in not-very-high-risk ASCVD after 2014.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partly supported by Fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Nanjing University School of Medicine (2022-LCYJ-PY-06 and 2022-YXZX-NFM-02)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The NHANES program was approved by the National Center for Health Statistics Ethics Review Board, and all participants provided written consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Funding: This work was partly supported by Fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Nanjing University School of Medicine (2022-LCYJ-PY-06 and 2022- YXZX-NFM-02).
Conflict of interest: None to declare.
Data Availability
All original data are available at the NHANES website.
Abbreviations
- ACEI
- angiotensin-converting enzyme inhibitor
- ASCVD
- atherosclerotic cardiovascular disease
- ARB
- angiotensin receptor blocker
- BMI
- body mass index
- CCB
- calcium channel blocker
- CHD
- coronary heart disease
- DPP-4
- dipeptidylpeptidase 4
- FBG
- fasting blood glucose
- GLP-1
- glucose like peptide-1
- HDL-C
- high-density lipoprotein cholesterol
- LDL-C
- low-density lipoprotein cholesterol
- (LDL-C) NHANES
- National Health and Nutrition Examination Surveys
- SGLT2
- sodium-glucose co-transporter-2
- TC
- total cholesterol
